Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease

A compound of Formula I:

• wherein:
• RA and RB are SO2N(R22)2, or one of RA and RB is SO3R23 and the other is hydrogen or SO3R23, or one of RA and RB is SO3−Y+ and the other is hydrogen, or one of RA and RB is CO2−Y+ and the other is hydrogen or CO2−Y+, or one of RA and RB is PO3−(Y+)2 and the other is hydrogen or PO3−(Y+)2;
• R2, R3, R4, R5, R6, R7, R8 and R9 are independently hydrogen, halogen, CF3, CN, C(O)R21, CO2R21, CO2−Y+, C(O)N(R22)2, OH, OR21, N(R12)2, N═C═S, NHC(O)R21, NHC(O)OR21, NHC(S)R21, NHC(S)N(R22)2, NHSO2R21, NHSO2N(R22)2, NO2, N2—R22, SOR21, SO2R21, SO3R21, SO3−Y+, OP(O)(OH)2, optionally substituted linear or branched C1-C10 alkyl, optionally substituted linear or branched C2-C10 alkenyl, optionally substituted linear or branched C2-C10 alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, provided that R3 and R8 are not the same;
• R21 is independently for each occurrence hydrogen, optionally substituted linear or branched C1-C10 alkyl, optionally substituted linear or branched C2-C10 alkenyl, optionally substituted linear or branched C2-C10 alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• R22 is independently for each occurrence hydrogen, optionally substituted linear or branched C1-C10 alkyl, optionally substituted linear or branched C2-C10 alkenyl, optionally substituted linear or branched C2-C10 alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl or C(O)(CH2)nCH3 wherein n=0, 1, 2, 3, 4, 5, or 6;
• R23 is independently for each occurrence optionally substituted linear or branched C1-C10 alkyl;
• Y+ is for each occurrence a cation;
• and
• pharmaceutically acceptable salts thereof.